EP0644754A4 - Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. - Google Patents
Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes.Info
- Publication number
- EP0644754A4 EP0644754A4 EP92901379A EP92901379A EP0644754A4 EP 0644754 A4 EP0644754 A4 EP 0644754A4 EP 92901379 A EP92901379 A EP 92901379A EP 92901379 A EP92901379 A EP 92901379A EP 0644754 A4 EP0644754 A4 EP 0644754A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bleeding
- powder
- surgery
- substance
- stop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000740 bleeding effect Effects 0.000 title claims abstract description 79
- 239000000843 powder Substances 0.000 title claims description 57
- 238000001356 surgical procedure Methods 0.000 title description 14
- 239000000126 substance Substances 0.000 title description 11
- 239000003814 drug Substances 0.000 title description 2
- 208000032843 Hemorrhage Diseases 0.000 claims description 76
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 238000007483 tonsillectomy Methods 0.000 claims description 3
- 206010017826 Gastric ulcer haemorrhage Diseases 0.000 claims description 2
- 208000034158 bleeding Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 32
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 6
- 229930003268 Vitamin C Natural products 0.000 abstract description 6
- 235000019154 vitamin C Nutrition 0.000 abstract description 6
- 239000011718 vitamin C Substances 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 4
- 239000008280 blood Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 26
- 208000009292 Hemophilia A Diseases 0.000 description 11
- 208000031220 Hemophilia Diseases 0.000 description 10
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 208000031169 hemorrhagic disease Diseases 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 8
- 238000005345 coagulation Methods 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 230000023555 blood coagulation Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000001105 femoral artery Anatomy 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 238000005507 spraying Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 229940089602 epinephrine injection Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000005900 regulation of collagen biosynthetic process Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000009429 hemophilia B Diseases 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Definitions
- P ⁇ TN ⁇ IK 1971 stated that the concentration of ascorbic acid has been reported as decrea ⁇ ingvith age in the rat eye lens, adrenal, brain, testis, and blood.
- Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people. Tattersal and Seville 1950 reported purpura in 60 out of 009 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and fore- ornv. and on tr.e backs of their hands, noth p-it ientj.
- THIS invention pertains to the field of disorder of hem ⁇ stasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboe bolic disorders.
- the blood coagulation mechanism of ascorbic acid which - was administered topically does not fall into either intrinsic or extrinsic pathway cascade, since it works the same for hemosta ⁇ i ⁇ in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in whom the coagulation factors 2, 7, 9, 10 in the liver dise and factor 8 or 9 in the hemophilia A or B cannot be produ
- the present methods available to stop bleeding in surger are cautery, epinephrine injection, pressure and some fiber foam.
- the cautery can cause tissue necrosis in some cases.
- the epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly >r* ⁇ ⁇ for diffuse capillary bleeding and any traditionally un ⁇ controllable bleeding tendency patients such as for patient with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency nf the kinds of aforementioned patients.
- the ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRN ⁇ in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
- Substance powder 001 represents ascorbic acid powder that i c obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding wnen spraying it topically on the bleeding area for any with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is needed to react completely with the blood is proportional to the amount of the blood that comes out of the blood vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficien amounts of the powder of ascorbic acid were applied. The arte bleeding needs much more this powder of interest.
- test tube conditions it requires 0.1568 g of this substance powde to coagulate ( make the blood black and not move in the tube 1 ml of human blood in 6 minutes.
- This is the same for normal colon cancer a d hemophilia patients; 1 ml of normal blood needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of hemophilia blood needs 0.1568 g of ascorbic acid powder.
- Suff substance powder 001 is particularly useful to help stop blee in the case of diffuse capillary oozing and mistakenly cut of artery or arteries that cannot be found during massive bleedi bleeding so as to save the patients' lives.
- the present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, press and some fiber foam.
- the cautery can cause tissue necrosis in some cases.
- the epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capillary oozi patients, while ascorbic acid powder does not cause any tissu necrosis and particularly works well for diffuse capillary bl and oozing and any traditionally uncontrollable bleeding tend patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients.
- the ascorbic acid also facilitate wound healing ( O Surg.
- the substance powder ool is made by grinding the pure vitamin C tablets into powder. Application of this powder topically to the bleeding area is betber'by spraying the powder topically on the bleeding area.
- the amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this * vitamin C powder to coagulate 1 ml of human blood. This ⁇ i ⁇ the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this s ⁇ tuation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows: (f) Rats Experiments
- Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off.
- Photograph # 1 massive bleeding when the femoral artery is cut off
- Photogrph # 2 bleeding stops within one second when sufficient powder of interest was poured topically into the bleeding area, in this case of massive active bleeding T did pouring instead of spraying.
- the amount of the powder needed is proportional to the amount of blood coming out of the vessel. It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off vithin one second.
- the black tar gel like material was formed in one second as soon as the powder contacts with the blood .
- This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
- tube con il.ion as mentioned previously, ] m ] of human b 1 .nor! requires 0.15C>fl q of powder to form Ma ⁇ -k bloori coa- qulatton by shaking the tube with hand or ⁇ color machine.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dental Preparations (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for stopping bleeding is described. The method entails applying to the site of bleeding powdered Vitamin C.
Description
SUBSTANCE THAT CAN STOP BLEEDING IN SURGICAL,MEDICAL AND DENTAL
USES/SUBSTANCE POWDER 001 THAT CAN STOP BLEEDING DURING SURGERY,
AFTER SURGERY, MEDECINE, DENTISTRY OR ANY BLEEDING DUE TO ANY CAUSES
SPECIFICATION OF INVENTION
(a) Title of the Invention.
The substance powder 001 that can stop (stanch) bleeding in surgical, postsurgical , medical and dental uses or any bleeding due to any causes by topical administration or the substance powder 001 that has very potent hemoεtatic action can be administered topically to stop bleeding during surgery, after surgery, medicine by inqestion, dental surgery, extraction of teeth, and any injury or due to any causes for any normal and pathological ρpr«?nn«?.
(b) Cross-References to Related Applications.
The early literature on scurvy due to vitamin r riefioeπry wa reviewed by Bourne in 1944, he shoved hieroglyphs from Egypti papyri as convincing evidence that this disease, charaterized by bleeding gums and hemorrhages in the skin, existed about 3000 years ayo. Λ sudden pain seized their feet, and leys; immediately afterwards the gums and teeth were attacked by a sort of gangrene. The bones of the legs become horribly black. The legs shrivelled up and became covered with black spots. It as a sure sign of death when the nose began to bleed. ( Hourne, G,H, 1944, Proc. K. Spc. Me . , 37, 51? ) PΛTNΛIK 1971 stated that the concentration of ascorbic acid has been reported as decreaεingvith age in the rat eye lens, adrenal, brain, testis, and blood. ( Patnaik, B.K. 1971, Gerontologia , 17, 122 ) Purpura (extensive bruising ) and hemorrhages under the tongue are common in elderly people. Tattersal and Seville 1950 reported purpura in 60 out of 009 elderly patients admitted to hospital; the bruises were most commonly seen on the anterior aspects of their arms and fore- ornv. and on tr.e backs of their hands, noth p-it ientj. an7 the controls were ascorbate deficient, as ju ged by ascorr.:r acid loading tests; skin biopsies from those vith purσura sho ed degeneration of tne collagen fibres rf the derππs. Tatttisa
(c) Background of the Invention.
(1) THIS invention pertains to the field of disorder of hemσstasis, which is further classified into evaluation of hemostatic function, platelet disorders, coagulation factor disorders and thromboe bolic disorders. However, the blood coagulation mechanism of ascorbic acid which - was administered topically does not fall into either intrinsic or extrinsic pathway cascade, since it works the same for hemostaεiε in normal situation as in chronic- hepatitis, colon cancer, and hemophilia patients in whom the coagulation factors 2, 7, 9, 10 in the liver dise and factor 8 or 9 in the hemophilia A or B cannot be produ (2) The present methods available to stop bleeding in surger are cautery, epinephrine injection, pressure and some fiber foam. The cautery can cause tissue necrosis in some cases. The epinephrine, pressure and fiber foam can not work for bleeding tendency patients, and fiber foam can cause tissue hemotoma, nor can they work for diffuse capillary bleeding and oozing, while ascorbic acid does not cause any tissue necrosis and works particularly >r*\ \ for diffuse capillary bleeding and any traditionally un¬ controllable bleeding tendency patients such as for patient with liver diseases, hemophilia and rectal anal cancer and for postoperation bleeding tendency nf the kinds of aforementioned patients. The ascorbic acid can facilitate wound healing also ( Oral Surg 1982 Mar: 53(3): 231-6 ) by increasing type 1 procollagen mRNΛ in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) (d) Explanation of Invention / Summary.
Substance powder 001 represents ascorbic acid powder that ic obtained by grinding the vitamin C tablets into powder. This powder has a very potent hemostatic action to stop bleeding wnen spraying it topically on the bleeding area for any
with the blood, the black tar gel like material is formed, and later becomes solid. The amount of the powder that is needed to react completely with the blood is proportional to the amount of the blood that comes out of the blood vessels. In rats, one capillary, one venous and one femoral artery bleeding were stanched within one second, if sufficien amounts of the powder of ascorbic acid were applied. The arte bleeding needs much more this powder of interest. In the test tube conditions, it requires 0.1568 g of this substance powde to coagulate ( make the blood black and not move in the tube 1 ml of human blood in 6 minutes. This is the same for normal colon cancer a d hemophilia patients; 1 ml of normal blood needs 0.1568 g of ascorbic acid powder, 1 ml of colon cancer blood needs 0.1568 g of ascorbic acid powder, and 1 ml of hemophilia blood needs 0.1568 g of ascorbic acid powder. Suff substance powder 001 is particularly useful to help stop blee in the case of diffuse capillary oozing and mistakenly cut of artery or arteries that cannot be found during massive bleedi bleeding so as to save the patients' lives.
The present methods available to stop bleeding in surgery as previously mentioned are cautery, epinephrine injection, press and some fiber foam. The cautery can cause tissue necrosis in some cases. The epinephrine, pressure and fiber foam can not cannot work for bleeding tendency and diffuse capillary oozi patients, while ascorbic acid powder does not cause any tissu necrosis and particularly works well for diffuse capillary bl and oozing and any traditionally uncontrollable bleeding tend patients such as for patients with liver diseases, hemophilia and colon rectal or other cancer bleeding conditions and for postoperation bleeding tendency of the kinds of aformentioned patients. The ascorbic acid also facilitate wound healing ( O Surg. 1982 Mar: 53 (3j: 231-6 ) by increasing type 1 procollag
mRNA in the regulation of collagen synthesis ( Atherosclerosis 1982 Jan: 41(1): 15-9 ) and when the vitamin C is absorbed into the system, it is good for health by making the leucocytes stronge and slowing the aging process etc, ( Patnaik and Kanungo 1964, Gerontologia, 10, 155 ) as long as it is within the optimal dose such as 1 g, However, at the end of operation before closure, the excessive black tar qel like material can be wiped away and washed with Ringer's feblutJion*
( e) Description of the preferred embodiments of the invention:
As already mentioned previously, the substance powder ool is made by grinding the pure vitamin C tablets into powder. Application of this powder topically to the bleeding area is betber'by spraying the powder topically on the bleeding area. The amount of vitamin C powder needed to spray is proportional to the amount of blood coming out of the vessels. In test tube conditions, it requires 0.1568 g of this* vitamin C powder to coagulate 1 ml of human blood. This λiε the same for normal, liver diseases, cancer, and hemophilia patients. The black coagulation takes place in 6 minutes by shaking the test tube. The description of this sβtuation is made in the evidence of animal ( rats ) experiments and clinical evidence as follows: (f) Rats Experiments
1) Sufficient substance powder 001 can stop massive bleeding of femoral artery within one second when femoral artery is cut off. ( Photograph # 1 : massive bleeding when the femoral artery is cut off ) ( Photogrph # 2: bleeding stops within one second when sufficient powder of interest was poured topically into the bleeding area, in this case of massive active bleeding T did pouring instead of spraying. The amount of the powder needed is proportional to the amount of blood coming out of the vessel. It varies with the rats. Usually 0.1344 g is sufficient to stop bleeding for the femoral artery of the rat which is cut off vithin one second. In the photograph # 2, the black tar gel like material
was formed in one second as soon as the powder contacts with the blood . Those white spots indicate the powder that is not yet mixed up with the blood. The black gel forms first on l.he surface of the pond of blood, that stop the fluid moving. If stirring the blood to break through the surface film like πtru that keep the blood fluid from moving when the powder is insuf it will bleed again, but slower than ( much slower ) before • t pouring the powder into the bleeding area; but after adding sufficient powder into the blood, stirring makes the powder molecules well saturated with the hemoglobin and plasma protei molecules and thus forming the concentrated black sticky gel li structure. After 5-6 minutes, when most of the sticky tar like structure is wiped away, it appears there is no bleeding at all. ( Photograph tf 3 ). In the case of capillary bleeding in which one capillary iε cut off, fibout 0. 0112 g of this powder can stop the bleeding within one second, ( Photograph # 4 ). After 1 minute count from adding the powder, it appears there is no more bleeding while wiping away the black tar qel like structure, while in the case of one vein cut off, it needs about 0.0224 g of the powder to stop bleeding, and about after 1 1/2 minutes, it appears there is no more bleeding when the black coagulation is wiped away. ( Photograph t 5 ) . The nostril was cut slightly to bleed ( Photograph # 6 ) in rat the bleeding stop within one second when applying this powder 0.0037 g topically into the bleeding nostril, ( Photograph # 7 ). After injection of histamin into the rat, it induces secretion of gastric acid, open up the stomach ( Photograph * G ), cut the mucosa layer to bleed ( Photograph # 9 ), applying the powder topically to the bleeding area, the black coagulatio formed, but slower than normal, since the secretion dilute the black coagulation. ( Photograph # 10) hup this powder can treat the gastric ulcer bleeding when it is inαested orally.
Clinical Evidence.
This powder also help stop massive bleeding in surgery, no matter what kind of diseases the patients suffered from.
Case 1. Age 32, male, scalp tumor excision, massive bleeding when the tumor vas exciεed. ( Photograph # I'l ) Sufficient spraying this powder into the bleeding area also help stop bleerling before it was closed by suture. ( Photo¬ graph # 1>2 ) Case 2. Age 40, female, acute renal failure, Λ-V fistula formation operation, massive bleeding ( Photograph * 1 _ ) The operation of stopping bleeding consiεts of combining the powder with press with gauze. When applying this powder to the bleeding area, those that look black in color indicate the black blood coagulation ( Photograph -ft lj_) ), while those that.are white in color are those the powder does not get mixed up with the blood ( Photograph 1'5 ). At the end of the operation, most of black blood coagulation was wiped out with 4x4 gau/.e, and rinsπrl with Ringer's solution ( Photograph # 1'6 ). It took totally 5 minuteε to stop the bleeding completely. The patient's conditions are especially well, better than without using this powder. Case 3* Age 40, male, skin contracture on the palm, which needs to be removed, and it requires skin graft.-
When the skin graft is removed from the hand,massive bleedi occurs ( Photograph # K7 ) . Qn applying sufficient powder to the bleeding area topically, it appears black coagulation within one second. Bleeding stops nt the same time ac the black coagulation forms. Those that appears white indicate the powder not yet mixed up with the blood. ( Photograph 4 18 ); those that appears more black area indicate the ππre powder mixed up with the blood (Photograph # 19 ), Suture going on ( Photograph * 2 )
Case 4 . Ληe 70 , f ema le , pa raana l abscess exci si on , bl eed i nq when i t i s opened up ( Photograph # 21 ) . When spra yi the powder to the bleeding area, it stop bleeding by forming black blood coagulation immediately. Those that appears white are the powder that are not mixed up with the blood. ( Photograph # 212), Suture going on ( Photograph # 23 ) . Case 5. Age 50, male, paraanal abscess excision. m---εive bleeding when it is opened up ( Photograph * 24 ). On spraying the powder topically to the bleedin area, the black color is formed im edi^ely because o the blood coagulation ( Photograph * 25 ) * The white color is the powder instantly not mixed up- with the blood yet. ( Photograph # 2r ), lastly, inp.Tt the long gauze into the anus. ( Photograph <t 21 ) Case f». Age 30, male, exiraction of tooth, the gum injected b ( Photograph t, 2 _ ). Applying this powder topically to the bleeding area, the bleeding stop within one sec and black blood coagulation forms within one second ( Photograph # 2§ ) . Wipe out the black coagulation in 10 seconds, stop bleeding still persisted ( Photo¬ graph * 3'0 ) Case 7. Age 60, female, chronic hepatitis, has bleeding tende extinction of teeth cause massive bleeding ( Photograp # 3'i ) On applying this powder to the socket of the gu the black coagulation forms within one second, the ble of Ihis socket εic b within one second a~cordingly . ( Photograph * 32 ) Case 0. myself, finger little scratched, slightly bleeds
( Pht.iograph * 33 ) . Upon contact with the powder, l he black color forms within one second or shorter ( Photo
PCT/US91/0920
In test, tube con il.ion as mentioned previously, ] m] of human b1.nor! requires 0.15C>fl q of powder to form Ma<-k bloori coa- qulatton by shaking the tube with hand or εtirer machine.
Tl. Lake;; G minutes t.o form the immobile black coaqυlatinπ in the tost t.uhe for normal, liver di.season, colon ranker and hemophilia hlood respectively. ( Photograph ft 3 _ normal blood, colon cancer Photograph # 3* ,, and hemophilia blood
Phuto'jraph i\ 3'7 ) This indicates that, the mechanism of the coagulation by this powder does not involve the coagulation factors. The hemophilia blood ( both prior to adding the powder and after adding powder) are still stored in the freezer here.
This patient's name: Su Jean Wang, Age 25, ma.le, 0.1.
# S 121745233, address: No 5, Su Ming Rd., Lane 100
Nan Tze District, Kaohsiung City / lastly, Stops bleeding in tonsillectomy rat within one second by topical use of th (f). Claims of Utilities of ascorbic acid powder. j
1. Stops bleeding in the nose bleeding in humans within one second, experi nced in my 6 years old dauqhl.er by applying this powder topically χ_ o her bleeding nostril.
' . Stops hlocdinq in any ijury due to any c.-πise, this also be useful for wound bleeding in the war or combat, zone.
'; . S o bleediπq in bleeding tendency patients in surgery or after surgery. Help stop bleeding in Λ-V fistula formation surgery in preparation for hemodialysis.
4. Stops bleeding in massive bleeding in scalp tumor excision. r-. Sto .'* lileediruj in bleeding tendency in paraπal. nbsress orci ion.
6. Stops bleeding in postoperation ( after surq ry ) bleeding Ϊti nni-itii'nm vrnmrl bleeding after rectal anal cancer surgery.
7. Stops bleeding in teeth extraction within one second in bleeding tendency patients when applying this powder topically to the bleeding socket of the gum.
8. Stops bleeding in the hemophilia patients due to injury when applying the powder topically to bleedinq area suf iciently.
9. Stops bleeding in Ob F» Gyn surgery in bleeding tendency
Claims
patients when applying this powder sufficiently to the bleeding area.
IC. Stops bleeding due to injury or bleeding due to any caus
11. Stops gastric ulcer bleeding when ingestion of this powd about 1 g / day orally.
12. Help stop and prevent internal bleeding when taking 1 g of this powder daily orally.
1?. «-np bleeding and help stop bleeding in tonsillectomy
,., . and after tonsillectomy bleeding. . __ ^
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62409490A | 1990-12-06 | 1990-12-06 | |
| US624094 | 1990-12-06 | ||
| PCT/US1991/009201 WO1992010999A1 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0644754A1 EP0644754A1 (en) | 1995-03-29 |
| EP0644754A4 true EP0644754A4 (en) | 1995-12-27 |
Family
ID=24500629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP92901379A Withdrawn EP0644754A4 (en) | 1990-12-06 | 1991-12-05 | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0644754A4 (en) |
| AU (1) | AU662505B2 (en) |
| CA (1) | CA2095439C (en) |
| NO (1) | NO930858D0 (en) |
| WO (1) | WO1992010999A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2336925A1 (en) * | 1975-12-30 | 1977-07-29 | Mouney Guy | Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc. |
| DE2808572A1 (en) * | 1977-03-04 | 1978-09-07 | Shiraimatsu Shinyaku Co | HAEMOSTATIC AGENT |
| WO1987006465A1 (en) * | 1986-04-22 | 1987-11-05 | Olav Johan Braenden | Anti-cold kit, anti-cold preparation and use thereof |
| WO1990012572A1 (en) * | 1989-04-17 | 1990-11-01 | Duke University | Stable ascorbic acid compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1334933A (en) * | 1971-02-19 | 1973-10-24 | Ahrens G W | Reaction products of caldium ascorbate and preparation containing them |
| US4959362A (en) * | 1983-12-19 | 1990-09-25 | Takeda Chemical Industries, Inc. | Pharmaceutical compositions containing certain ascorbic acid derivatives useful in the prophylaxis and treatment of disorders of the circulatory system |
| US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
-
1991
- 1991-12-05 WO PCT/US1991/009201 patent/WO1992010999A1/en not_active Ceased
- 1991-12-05 EP EP92901379A patent/EP0644754A4/en not_active Withdrawn
- 1991-12-05 AU AU91034/91A patent/AU662505B2/en not_active Ceased
- 1991-12-05 CA CA 2095439 patent/CA2095439C/en not_active Expired - Fee Related
-
1993
- 1993-03-09 NO NO1993930858A patent/NO930858D0/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2336925A1 (en) * | 1975-12-30 | 1977-07-29 | Mouney Guy | Dentifrice contg. haemostatic agent, esp. ascorbic acid or salt - has curative action on lesions of gingival epithelium etc. |
| DE2808572A1 (en) * | 1977-03-04 | 1978-09-07 | Shiraimatsu Shinyaku Co | HAEMOSTATIC AGENT |
| WO1987006465A1 (en) * | 1986-04-22 | 1987-11-05 | Olav Johan Braenden | Anti-cold kit, anti-cold preparation and use thereof |
| WO1990012572A1 (en) * | 1989-04-17 | 1990-11-01 | Duke University | Stable ascorbic acid compositions |
Non-Patent Citations (4)
| Title |
|---|
| ANTOSZEWSKI Z: "Zastosowanie preparatu Cepevit-K do tamowania krwawien i krwotokow po usunieciu zebow.", POL TYG LEK (POLAND), NOV 20 1972, VOL. 27, NO. 47, PAGE(S) 1861-2, * |
| DATABASE MEDLINE GURNEY B.F.: "Hemostatic Agents" * |
| ORAL HYG., vol. 56, no. 7, 1966, pages 78 - 80 * |
| See also references of WO9210999A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992010999A1 (en) | 1992-07-09 |
| EP0644754A1 (en) | 1995-03-29 |
| CA2095439A1 (en) | 1992-06-07 |
| AU662505B2 (en) | 1995-09-07 |
| AU9103491A (en) | 1992-07-22 |
| NO930858D0 (en) | 1993-03-09 |
| CA2095439C (en) | 1998-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5510391A (en) | Method of treating blood vessel disorders of the skin using vitamin K | |
| US6455067B1 (en) | Transdermal patch for nonsteroidal antiinflammatory drug(s) | |
| KR101283820B1 (en) | Oral compositions for absorption of phosphorus compounds | |
| TWI287447B (en) | Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia | |
| Ramasastry | Chronic problem wounds | |
| Rao et al. | Extravasation injury to the hand by intravenous phenytoin: report of three cases | |
| WO2024260450A1 (en) | Use of water-soluble tomato concentrate in preparation of composition for treating cerebral ischemia-reperfusion injury | |
| Sigurdsson et al. | Formic acid burn—Local and systemic effects report of a case | |
| EP0532706B1 (en) | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS | |
| US5114974A (en) | Treatment of atherosclerosis with MgNa2 EDTA | |
| AU662505B2 (en) | Substance that can stop bleeding in surgical, medical and dental uses/substance powder 001 that can stop bleeding during surgery, after surgery, medicine, dentistry or any bleeding due to any causes | |
| Lee et al. | Hemostatic materials in non-variceal upper gastrointestinal hemorrhage | |
| ES2346649T3 (en) | COMPRESSED COVERED WITH A FILM THAT INCLUDES AN EXTRACT OF RED PARRA LEAVES. | |
| Smith et al. | Clinical features in patients with the carcinoid syndrome | |
| US6783774B1 (en) | Substance that stop any kind of bleeding within one second for medical, surgical, postsurgical and dental uses | |
| Lau et al. | Wound care in the elderly patient | |
| RU2442597C1 (en) | Method for obtaining extract of unripe walnuts, used in medicine, cosmectics and as food (biologically active additives) | |
| Villanueva et al. | Dermatologic Manifestations in Renal Disease | |
| Collings et al. | Three cases of inoculation of tuberculosis from tattooing | |
| CA3073146C (en) | Use of 2-[(3z)-6-fluoro-2-methyl-3-[(4-methylsulfinylphenyl)methylidene]inden-1--yl] acetic acid for making a healing preparation for wounds in patients with diabetes | |
| Krishna | Study of Surgincal Complicatons in Diabetic Patients Among The Rural Population | |
| Bacigalupo et al. | The effect of heparinization upon vascular healing | |
| Chandler et al. | Benign duodeno-colonic fistula | |
| Green | Pathology and morbid anatomy | |
| Holman et al. | Hypoproteinemia as protection against mercuric chloride injury in dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19940428 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE |
|
| RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH DE DK ES FR GB IT LI LU MC NL SE |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 19950626 |
|
| AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB IT LI LI MC NL SE SE |
|
| 17Q | First examination report despatched |
Effective date: 19980803 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| 17Q | First examination report despatched |
Effective date: 19980803 |
|
| GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
| GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
| APAB | Appeal dossier modified |
Free format text: ORIGINAL CODE: EPIDOS NOAPE |
|
| APBX | Invitation to file observations in appeal sent |
Free format text: ORIGINAL CODE: EPIDOSNOBA2E |
|
| APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20050701 |